Quarterly results round-up: US Sapien sales drive up Edwards' Q2; QGEN, TMO, VAR
This article was originally published in Clinica
Edwards Lifesciences saw its bottom and top lines grow during its second fiscal quarter, driven by increasing US sales of its Sapien transcatheter heart valve, which offset softness in Europe. Morgan Stanley analyst David Lewis described the European market as "a challenge", but said the problems there "could not overshadow Sapien['s] performance in the US". US Sapien sales of $61m in Q2 outpaced the analyst's forecast of $53m.